C5a and thromboxane generation associated with pulmonary vaso- and broncho-constriction during protamine reversal of heparin.
The authors conducted a study in humans to determine the mediators associated with acute pulmonary vaso- and broncho-constriction occurring episodically with protamine reversal of heparin anticoagulation. Of 48 adult patients investigated prospectively after termination of cardiopulmonary bypass, two presented a sudden increase of airway pressure, acute pulmonary hypertension, and systemic hypotension 1-3 min after right atrial protamine injection. In these two subjects, plasma levels of C5a increased from 0.7 and 2.2 to 9.8 and 9.9 ng/ml, respectively, and thromboxane B2 increased from 0.26 and 0.34 to 7.5 and 16.2 ng/ml 1 minute after drug injection. A third subject not identified prospectively had an identical reaction and mediator profile (C5a, 10.2 ng/ml; TxB2, 18.6 ng/ml at 1 min). The plasma levels of these mediators were unchanged in the remaining patients (C5a, 0.7 +/- 1.1 [x +/- S.D.] to 0.6 +/- 0.9 ng/ml; TxB2, 0.16 +/- 0.12 to 0.15 +/- 0.07 ng/ml). Plasma histamine was not involved in this type of reaction, but increased from 0.7-10.4 ng/ml in a fourth patient who became hypotensive without acute pulmonary hypertension, bronchoconstriction, or elevation of C5a or TxB2. The authors' data indicate that the generation of high plasma levels of C5a anaphylatoxins and thromboxane is associated with pulmonary vaso- and broncho-constriction induced by protamine reversal of heparin in humans.
D000328:Adult; D000368:Aged; D001980:Bronchi / Q000187:drug effects*; D003176:Complement C3 / Q000032:analysis; D015926:Complement C3a; D003181:Complement C4 / Q000032:analysis; D015934:Complement C4a; D003182:Complement C5 / Q000096:biosynthesis*; D015936:Complement C5a; D006439:Hemodynamics / Q000187:drug effects; D006632:Histamine / Q000097:blood; D006801:Humans; D007958:Leukocyte Count; D008875:Middle Aged; D010976:Platelet Count; D011479:Protamines / Q000009:adverse effects*; D011652:Pulmonary Circulation / Q000187:drug effects*; D013931:Thromboxanes / Q000096:biosynthesis*; D014661:Vasoconstriction / Q000187:drug effects*
D003176:Complement C3; D003181:Complement C4; D003182:Complement C5; D011479:Protamines; D013931:Thromboxanes; D015926:Complement C3a; D015934:Complement C4a; D015936:Complement C5a; D006632:Histamine